Preparation of Novel Co/ZIF-8 Nanocomposites and Evaluation of Their Anticancer Cell Performance in Vitro

Chen Yu-fei; Fan Bo-hua; Chu Hui-yuan

doi:doi:10.11648/j.sd.20251306.14

Research Article |

| Peer-Reviewed

Preparation of Novel Co/ZIF-8 Nanocomposites and Evaluation of Their Anticancer Cell Performance in Vitro

Chen Yu-fei

, Fan Bo-hua

, Chu Hui-yuan^*

Published in Science Discovery (Volume 13, Issue 6)

Received: 30 September 2025 Accepted: 6 November 2025 Published: 10 December 2025

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

To address the inherent limitations of single-mode cancer therapy—such as low efficacy, high susceptibility to drug resistance, and the inability to completely eliminate residual tumor cells—this study innovatively adopted an ion-doping strategy to successfully fabricate Co²⁺-doped ZIF-8 small nanocrystal carriers under mild room temperature conditions, avoiding harsh reaction environments that may impair material performance. Endowed with a unique porous structure and large specific surface area, the as-prepared carrier exhibited excellent drug-loading performance, achieving a maximum loading capacity of 84.4% for the widely used chemotherapeutic agent doxorubicin (DOX). Thus, a synergistic nanotherapeutic system (CFD) integrating chemodynamic therapy and chemotherapy was rationally constructed to leverage the complementary advantages of both modalities. In vitro cell experimental results demonstrated that after 24 hours of incubation, the chemo/chemodynamic synergistic nanosystem exerted a lethality rate of up to 87.1% against HeLa cervical cancer cells, which was significantly superior to that of either monotherapy (single chemotherapy or chemodynamic therapy alone). This finding fully confirms that the CFD nanotherapeutic system possesses potent in vitro anticancer activity, as it can synergistically leverage the merits of both treatment modalities to enhance therapeutic efficacy and effectively overcome the limitations of single-mode therapy. Collectively, this work provides a reliable experimental foundation and promising application prospects for subsequent in-depth in vivo tumor therapy research and potential clinical translation.

Published in	Science Discovery (Volume 13, Issue 6)
DOI	10.11648/j.sd.20251306.14
Page(s)	125-130
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2025. Published by Science Publishing Group

Keywords

Co/ZIF-8 Nanomaterials, DOX, Anti-cancer

1．引言

癌症作为严重威胁人类健康的重大疾病，全球癌症发病率和死亡率不断上升

[1]

，纳米技术的快速发展为癌症治疗带来了新契机。纳米材料因其独特的物理化学性质，如小尺寸效应、表面效应和量子尺寸效应，在药物递送、诊断和治疗等生物医学领域展现出很大的应用潜力

[2]

。根据其具备的优点，制备新型了 Co/ZIF-8 纳米材料，通过优化制备方法，调控材料的结构和性能，对所制备的纳米材料进行表征，利用多种表征技术，如使用透射电子显微镜（TEM）、傅立叶红外光谱仪等

[3]

，对制备的 Co/ZIF - 8 纳米材料的晶体形貌、尺寸、粒径分布、官能团等进行表征

[4]

，深入了解材料的物理化学性质。将 DOX 负载到 Co/ZIF - 8 材料中，进行细胞毒性检测实验，观察对癌细胞的杀伤作用

[5]

。图1为整个过程的流程图，上半部分(A)展示了 Co/ZIF - 8 及 Co/ZIF - 8@DOX 的制备过程。起始是含 Zn²⁺、Co^{2 +}的有机配体结构，在室温（RT）下反应5小时，形成 Co/ZIF - 8（金属-有机框架材料），之后 Co/ZIF - 8 负载阿霉素（DOX），得到 Co/ZIF - 8@DOX，用于后续药物的递送。下半部分（B）呈现Co/ZIF - 8@DOX作用于癌细胞（Cancer cell）的过程。Co/ZIF - 8@DOX 进入癌细胞后，在低 pH 环境下，发生降解，释放出 Co²⁺和 DOX。DOX 通过化疗作用，直接损伤癌细胞的 DNA

[6]

；释放出的 Co²⁺与癌细胞内的 H₂O₂发生反应，通过类芬顿反应产生活性氧（•OH），启动化学动力学治疗，进一步损伤癌细胞的DNA，实现化疗与化学动力学治疗协同杀伤癌细胞的目的。这种基于纳米材料的药物递送及治疗策略，有望在癌症治疗领域发挥作用。

Download: Download full-size image

Figure 1. 图1 流程图。

2．实验部分

2.1．试剂和仪器

2-甲基咪唑，AR, 上海阿拉丁生化科技公司；氯化钴，AR, 北京北化精细化学品公司；氯化锌，AR，福晨化学试剂有限公司；阿霉素，AR，上海阿拉丁生化科技股份有限公司；过氧化氢，AR，广东恒建制药有限公司；3,3',5,5'-四甲基联苯胺，AR，湖北汉威化工有限公司。

磁力恒温搅拌器，上海梅颖浦仪器；离心沉淀器，湖南多恒仪器设备有限公司：JFZD-200B恒温振荡器，杭州仪器科技有限公司；紫外可见分光光度计，上海菁华科技仪器；傅立叶红外光谱仪，深圳华科计算检测技术有限公司；酶标检测仪，Biotek。

2.2．Co/ZIF-8的制备

称取 1.18g 氯化锌和 0.19g 氯化钴溶解于 50mL 蒸馏水中,将5.55g 2-甲基咪唑溶解于另 50mL 蒸馏水中，把两份溶解好的溶液倒入单口烧瓶内，用磁力搅拌器在恒温下搅拌5小时。反应结束后，离心，烘干，即为 Co/ZIF - 8 材料

[7]

。

2.3．DOX溶液的配制

称取1、2、3、4、5 mg 的 DOX，在烧杯中溶解后，分别倒入 50mL 容量瓶中，并用蒸馏水定容。即制得浓度为 20、40、60、80、100 ug/mL 的 DOX 溶液。

2.4．探究 Co/ZIF-8 对不同浓度DOX的负载

从 20、40、60、80、100 ug/mL DOX 溶液中各取出 5mL 溶液，分别加入 2mg Co/ZIF-8 材料，放入恒温振荡器中进行负载1 h，负载完成后离心，取上清液，分别测其吸光度 A₁、A₂、A₃、A₄、A₅，带入 DOX 标准曲线方程y=0.0086x-0.0117 算出浓度，最后带入负载公式算出负载量

[8]

。

负载量=（药物总量-游离药物量）/纳米颗粒重量

2.5．CFD的制备

往烧杯中加 20 mg Co/ZIF-8 材料和 50mL 浓度为 80ug/mL 的 DOX 溶液，用超声波处理 3 分钟，充分溶解后放入振荡器中震荡 1小时，震荡结束后将溶液进行离心分离，在转速为 12000 r/min 的离心机下离心 8 分钟。离心完成后，对沉淀物进行清洗，清洗结束后再次进行离心分离。最后将沉淀物收集，在 36.5°C 烘箱中烘干，即为 Co/ZIF-8@DOX (CFD)。

2.6．CFD 的pH响应性DOX释放特性

我们对 CFD 的 pH 响应 DOX 释放特性进行了测试。取 2mg 的材料加 5mL 配制好的 80ug/mL 的 DOX 负载一小时。离心，去上清液，加 5ml 磷酸盐缓冲液（pH 5.0、pH 6.8或 pH 7.4），释放10、15、20、25 min，通过紫外-可见光谱测 DOX 浓度，以计算 DOX 的释放率由公式

[9]

M (t) —— 时间t时药物释放的总质量，M∞ —— 代表可释放药物的最大质量一般采用极端环境下的释放量来衡量。

2.7．•OH 自由基的检测

用3,3',5,5'-四甲基联苯胺作为探针来评估 CFD 生成·OH 的能力，在磷酸盐缓冲液（0.1 M，pH 5.0）中，不同浓度的 CFD 与 H₂O₂（1.0 mM）和 3,3',5,5'-四甲基联苯胺（1.0 mM）反应，溶液在 654 nm 处的吸光度用于评估在酸性介质中生成 •OH 的能力

[10]

。

2.8．细胞毒性检测

2.8.1．细胞复苏

打开水浴锅，调整温度为 37°C。取出 -80°C冻存的海拉细胞（HeLa Cells），将细胞快速置于水浴锅中，并且快速晃动，待细胞完全融化后，将冻存管从水浴锅中取出，取 1 支 15 mL 无菌离心管，加入 7 mL 培养基，然后加入冻存管中的细胞，室温下1000 rpm，离心 5 min

[11]

。取一个新的 25T 细胞培养瓶，加入 5 mL 含 10% FBS 的培养基，将离心管中的上清弃去，留下沉淀，取 1 mL 培养基重悬后全部加入到培养瓶中，5% CO2，37°C条件下，静置 8 h，然后吸走全部培养基，加入5 mL 新鲜的含 10% FBS 的培养基，继续培养，等到细胞长满培养瓶即可

[12]

。

2.8.2．MTT具体步骤

实验分为：空白对照；阴性对照；样品组。

种板前先吸掉培养瓶中的培养基，用 PBS 洗 1 次，加入 0.25% 胰蛋白酶消化细胞。倒掉胰蛋白酶后，加入含 10% 胎牛血清的完全培养基吹打细胞，并转入加样槽中吹匀，用细胞计数板计数，按照 1×104个细胞/孔 100 μL，将细胞铺在 96 孔板中，置于培养箱中培养 12 h

[13]

。根据实验要求，将样品 1、2、3、4 分别按照对应浓度在培养基中分散均匀后加入细胞 96 孔板中，继续培养 24h。每孔加入 10μL MTT 溶液（5mg/mL），继续培养 4 小时。小心吸掉上清，每孔加入 100μL 二甲基亚砜，置摇床上低速振荡 10 分钟，使结晶物充分溶解，在酶联免疫检测仪 570nm 波长处测定各孔的光吸收值如表1、2所示

[14]

。

细胞存活率的计算公式如下

[15]

：

细胞存活率(%) = (OD值-空白对照) / (阴性对照-空白对照)× 100%

阴性对照——Control，样品组——OD值。

3．结果与讨论

3.1．Co/ZIF-8 电镜图

将制备好的Co/ZIF-8分散在乙醇中通过透射电子显微镜仪器观测后，得出电镜图。由2左图可以看出Co/ZIF-8材料粒子的分散性较好，多个星形粒子在视野中较为均匀地分布，彼此之间有明显的间距，没有出现粒子团聚的现象。根据图2右侧显微图像分析，Co/ZIF-8粒子在微观尺度下呈现类星形的几何构型，粒径大小约为500 nm。

Download: Download full-size image

Figure 2. 图2 合成的 Co/ZIF-8 材料的电镜图。

3.2．傅立叶红外光谱图分析

我们用 FT-IR 对 Co/ZIF-8、DOX 及Co/ZIF-8@DOX 结构中的官能团进行了分析。在 4000-400cm−1的范围内，Co/ZIF-8、DOX 及 Co/ZIF-8@DOX 的 FT-IR 光谱如图3所示。我们分析 DOX 的红外光光谱图可以确定其特征吸收峰分别在1016 cm−1（此位置吸收峰常与C - O - C 醚键或P - O - P 等类似结构的伸缩振动有关）和1469 cm−1处（该峰与C = C 或C = N 双键的伸缩振动有关）。而 Co/ZIF-8 吸附 DOX 的材料 Co/ZIF-8@DOX 在 1016 cm−1和1469cm−1 处也表现出很强的吸收峰。所以，我们可以确定 Co/ZIF-8 对 DOX 有一定的吸附能力。

Download: Download full-size image

Figure 3. 图3 合成的 Co/ZIF-8 材料与负载 DOX 前后的红外光谱。

3.3．Co/ZIF-8负载量数据分析

我们得到了各个时间点的负载量分别为 35.8%，57.9%，77.3%，80.4% 和 64.8%，在 DOX 浓度为 80 ug/mL 时，Co/ZIF-8 材料表现出最大的负载量，达到了 84.4%。从中可以确定最大负载量为 84.4%。

这些结果对于进一步评估和优化 CFD 的应用于化疗具有重要意义，并为后续研究提供了实验依据。

3.4．CFD的释放率分析

从图4中可以看出，在 25 min，pH 5.0 的条件下释放率可以达到 43.2%，而同样 25min 下，pH6.8 和 pH7.4 的释放率分别为 11.2% 和 12.9%，pH 5.0 是 pH6.8 和 pH7.4 条件下的近2倍。由此可知，CFD 在酸性环境里具有良好的 DOX 释放性。这种 pH 敏感材料可以实现药物选择性输送到肿瘤组织，从而发挥更好的治疗效果。

Download: Download full-size image

图4 CFD在pH为5. .0、6.8或7.4（37°C）的条件下，DOX的释放曲线DOX负载量随DOX浓度变化。

3.5．CFD生成•OH的评价

Download: Download full-size image

Figure 5. 图5 在25°C和1mM H₂O₂条件下不同浓度的CFD反应5min后的吸收光谱。

为了证明 CFD 在 H₂O₂ 存在下能产生 •OH，我们使用3,3',5,5'-四甲基联苯胺作为探针来监测 •OH 的产生，无色的3,3',5,5'-四甲基联苯胺可被·OH 氧化成显色的3,3',5,5'-四甲基联苯胺阳离子自由基，其特征最大吸收波长为 654 nm。当环境 pH 值维持在 5.0 时，对不同浓度 CFD 溶液进行检测。实验数据显示（图5），随着 CFD 浓度由 0 ug/ml 逐步递增至 150 ug/ml，654 nm 波长处的吸光度值相应地从 0.16 升至 0.32。该光谱响应变化特征表明，在酸性条件下，CFD 具备高效产生 •OH 的能力。

3.6．CFD体外抗癌细胞实验的数据分析

表1 Co/ZIF - 8细胞毒性检测数据。

Co/ZIF - 8组	OD值						平均值
200	0.35	0.263	0.341	0.353	0.412	0.322	——
100	1.426	1.445	1.432	1.451	1.472	1.468	——
50	1.515	1.523	1.567	1.548	1.565	1.578	——
25	1.656	1.693	1.525	1.537	1.623	1.478	——
12.5	1.605	1.581	1.713	1.658	1.594	1.568	——
Control	1.598	1.595	1.727	1.693	1.658	1.732	1.667
空白对照	0.052	0.052	0.051	0.051	0.052	0.051	0.052

表2 Co/ZIF-8@DOX细胞毒性检测数据。

Co/ZIF-8@DOX组	OD值						平均值
200 100	0.275	0.282	0.312	0.225	0.232	0.218	——
200 100	0.359	0.363	0.332	0.347	0.351	0.320	——
50	0.342	0.343	0.276	0.324	0.316	0.274	——
25	0.314	0.311	0.257	0.299	0.292	0.254	——
12.5	0.377	0.377	0.300	0.350	0.332	0.294	——
Control	1.663	1.607	1.635	1.663	1.656	1.671	1.649
空白对照	0.050	0.051	0.052	0.051	0.051	0.051	0.051

Download: Download full-size image

Figure 6. 图6 癌细胞相对存活率。

1. 对照组（Control）

在对照组中，细胞相对活力均接近100% 。这表示在未添加抗癌物质时，癌细胞处于正常生长状态，细胞活力未受到抑制，为后续不同浓度处理组提供了参考标准。

2. 不同浓度处理组

①低浓度（12.5 μg/mg）：CO/ZIF-8 处理组细胞相对活力仍维持在较高水平，与对照组接近，说明该浓度下 CO/ZIF-8 对癌细胞活力抑制作用比较小。而 CO/ZIF-8@DOX 处理组细胞相对活力明显下降，下降至17.9% 。这说明 CO/ZIF-8@DOX 在较低浓度时就对癌细胞有明显杀伤或抑制增殖效果。

②中浓度（25 μg/mg、50 μg/mg）：CO/ZIF-8 处理组细胞相对活力慢慢降低，但还是维持在较高比例。25 μg/mg 时细胞相对活力是 94.9%，50 μg/mg 时是 92.7%。CO/ZIF-8@DOX 处理组细胞相对活力在这两个浓度下都比较低，而且数值相近，在 14% - 17% 之间。这说明 CO/ZIF-8@DOX 在中浓度下抑制癌细胞的效果很稳定，也很明显，CO/ZIF-8 的抑制效果就较弱。

③高浓度（100 μg/mg、200 μg/mg）：CO/ZIF-8 处理组细胞相对活力继续降低。100 μg/mg 时细胞相对活力是 86.5%，200 μg/mg 时是 17.9% 。CO/ZIF-8@DOX 处理组细胞相对活力在 100 μg/mg 时是 18.4%，200 μg/mg 时是 12.9% 。这时虽然 CO/ZIF-8 抑制癌细胞的作用变强了，但 CO/ZIF-8@DOX 一直让细胞活力保持在较低水平，说明它的抗癌能力更强。

4．结论

本实验采用室温合成法制备Co/ZIF-8复合材料。使用透射电子显微镜（TEM）和傅里叶变换红外光谱（FT-IR）检测材料的微观结构和化学性质。TEM观察发现，合成的Co/ZIF-8材料形状为星形，粒子的分散性较好，说明材料合成成功。

接下来，研究材料对阿霉素的负载能力。负载实验结果显示，在 DOX 浓度为 80 ug/mL 时，Co/ZIF-8 材料的最大负载量为 84.5%，再观察负载 DOX 前后的傅立叶红外光谱图，发现负载后的 Co/ZIF-8@DOX 生成了很强的吸收峰，证明 Co/ZIF-8 材料具有较好负载 DOX 的能力，并成功合成了 Co/ZIF-8@DOX 纳米复合材料；释放实验表明在酸性环境下释放效果更好；自由基检测实验表明 CO/ZIF-8@DOX 在酸性环境中可以有效生成 • OH；细胞实验结果表明，Co/ZIF-8纳米复合材料通过协同化疗/化学动力学治疗对癌细胞具有显著的抑制作用，展现出良好的抗癌应用潜力。

基金项目

2024年内蒙古自治区人才开发基金；内蒙古自治区教育厅自然科学一般项目（NJZY22246）；河套学院自然科学一般项目（HYZY202103）；创新创业训练计划项目（202311631016；202411631006；202411631012）；内蒙古自然科学基金（2024MS02022)

ORCID

0009-0004-3777-7021 (Chen Yu-fei)

0009-0000-7784-5501 (Fan Bo-hua)

0009-0006-3728-2381 (Chu Hui-yuan)

References

[1]	滕熠,张晓丹,夏昌发,等.中国与全球癌症发病、死亡和患病对比及其预测分析:GLOBOCAN 2022数据解读[J].中华肿瘤防治杂志, 2024, 31(23): 1413-1420. https://doi.org/10.16073/j.cnki.cjcpt.2024.23.01
[2]	王峻. 纳米囊泡药物载体系统的构建及其在结直肠癌靶向治疗的应用研究[D]. 长春工业大学, 2025. https://doi.org/10.27805/d.cnki.gccgy.2025.001234
[3]	张松涛,林子夏,周俊,等. 电子显微镜在化学化工类本科教学中的探索 [J]. 当代化工研究, 2025, (04): 136-138. https://doi.org/10.20087/j.cnki.1672-8114.2025.04.044
[4]	周强. 基于生物质前驱体制备碳纳米复合材料及其电化学性能研究[D]. 湖南大学, 2019. https://doi.org/10.27135/d.cnki.ghudu.2019.001018
[5]	张善纯,程祥玉,宋蓉,等. 钛表面ZIF-L涂层的构建及细胞毒性检测 [J]. 哈尔滨医科大学学报, 2024, 58 (01): 100-104. https://doi.org/10.20010/j.issn.1000-1905.2024.01.0100
[6]	龚姗,白波,李苗,等. 细胞分裂周期相关蛋白3在卵巢癌发生发展中的作用及对化疗敏感性影响的机制研究 [J]. 中国优生与遗传杂志, 2025, 33 (03): 513-524. https://doi.org/10.13404/j.cnki.cjbhh.2025.03.027
[7]	张俊雄,张宇慧,沈静. ZIF-8及复合材料的合成与研究进展 [J]. 辽宁化工, 2025, 54 (02): 283-287. https://doi.org/10.14029/j.cnki.issn1004-0935.2025.02.013
[8]	殷逸梅. 基于分子印迹的新型智能生物材料表面的设计与应用研究[D]. 江苏科技大学, 2021. https://doi.org/10.27171/d.cnki.ghdcc.2021.000560
[9]	李晓静. 基于菁染料光敏感纳米粒子的构建及在肿瘤治疗中的应用[D]. 大连理工大学, 2021. https://doi.org/10.26991/d.cnki.gdllu.2021.004864
[10]	楚惠元.增强化学动力学疗法的多功能纳米治疗体系的构建及体外治疗性能评价 [D]. 西北大学, 2022. https://doi.org/10.27405/d.cnki.gxbdu.2022.00117
[11]	黄可榆. 负载Nisin的果胶微胶囊的制备及其对芒果保鲜效果的研究 [D]. 广西大学, 2022. https://doi.org/10.27034/d.cnki.ggxiu.2022.001117
[12]	栾小芳. BODIPY型次氯酸荧光探针的设计合成及性质研究 [D]. 烟台大学, 2024. https://doi.org/10.27437/d.cnki.gytdu.2024.000293
[13]	马英中. 吻合钉用高强韧可控降解Mg-Zn-Ca-X的合金化规律与组织性能研究 [D]. 北京科技大学, 2022. https://doi.org/10.26945/d.cnki.gbjku.2022.000270
[14]	孙琳琳. 玉米中黄曲霉毒素B1的酶联和比率荧光免疫检测方法研究 [D]. 长江大学, 2024. https://doi.org/10.26981/d.cnki.gjhsc.2024.001028
[15]	昌天鹤, 全姬善. pH敏感脂质体在肿瘤治疗领域的研究进展 [J]. 河南大学学报(医学版), 2024, 43 (03): 157-161. https://doi.org/10.15991/j.cnki.41-1361/r.2024.03.002

Cite This Article

Plain Text BibTeX RIS

APA Style

Yu-fei, C., Bo-hua, F., Hui-yuan, C. (2025). Preparation of Novel Co/ZIF-8 Nanocomposites and Evaluation of Their Anticancer Cell Performance in Vitro. Science Discovery, 13(6), 125-130. https://doi.org/10.11648/j.sd.20251306.14

Copy | Download

ACS Style

Yu-fei, C.; Bo-hua, F.; Hui-yuan, C. Preparation of Novel Co/ZIF-8 Nanocomposites and Evaluation of Their Anticancer Cell Performance in Vitro. Sci. Discov. 2025, 13(6), 125-130. doi: 10.11648/j.sd.20251306.14

Copy | Download

AMA Style

Yu-fei C, Bo-hua F, Hui-yuan C. Preparation of Novel Co/ZIF-8 Nanocomposites and Evaluation of Their Anticancer Cell Performance in Vitro. Sci Discov. 2025;13(6):125-130. doi: 10.11648/j.sd.20251306.14

Copy | Download

@article{10.11648/j.sd.20251306.14,
  author = {Chen Yu-fei and Fan Bo-hua and Chu Hui-yuan},
  title = {Preparation of Novel Co/ZIF-8 Nanocomposites and Evaluation of Their Anticancer Cell Performance in Vitro
},
  journal = {Science Discovery},
  volume = {13},
  number = {6},
  pages = {125-130},
  doi = {10.11648/j.sd.20251306.14},
  url = {https://doi.org/10.11648/j.sd.20251306.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sd.20251306.14},
  abstract = {To address the inherent limitations of single-mode cancer therapy—such as low efficacy, high susceptibility to drug resistance, and the inability to completely eliminate residual tumor cells—this study innovatively adopted an ion-doping strategy to successfully fabricate Co2+-doped ZIF-8 small nanocrystal carriers under mild room temperature conditions, avoiding harsh reaction environments that may impair material performance. Endowed with a unique porous structure and large specific surface area, the as-prepared carrier exhibited excellent drug-loading performance, achieving a maximum loading capacity of 84.4% for the widely used chemotherapeutic agent doxorubicin (DOX). Thus, a synergistic nanotherapeutic system (CFD) integrating chemodynamic therapy and chemotherapy was rationally constructed to leverage the complementary advantages of both modalities. In vitro cell experimental results demonstrated that after 24 hours of incubation, the chemo/chemodynamic synergistic nanosystem exerted a lethality rate of up to 87.1% against HeLa cervical cancer cells, which was significantly superior to that of either monotherapy (single chemotherapy or chemodynamic therapy alone). This finding fully confirms that the CFD nanotherapeutic system possesses potent in vitro anticancer activity, as it can synergistically leverage the merits of both treatment modalities to enhance therapeutic efficacy and effectively overcome the limitations of single-mode therapy. Collectively, this work provides a reliable experimental foundation and promising application prospects for subsequent in-depth in vivo tumor therapy research and potential clinical translation.
},
 year = {2025}
}

Copy | Download

TY  - JOUR
T1  - Preparation of Novel Co/ZIF-8 Nanocomposites and Evaluation of Their Anticancer Cell Performance in Vitro

AU  - Chen Yu-fei
AU  - Fan Bo-hua
AU  - Chu Hui-yuan
Y1  - 2025/12/10
PY  - 2025
N1  - https://doi.org/10.11648/j.sd.20251306.14
DO  - 10.11648/j.sd.20251306.14
T2  - Science Discovery
JF  - Science Discovery
JO  - Science Discovery
SP  - 125
EP  - 130
PB  - Science Publishing Group
SN  - 2331-0650
UR  - https://doi.org/10.11648/j.sd.20251306.14
AB  - To address the inherent limitations of single-mode cancer therapy—such as low efficacy, high susceptibility to drug resistance, and the inability to completely eliminate residual tumor cells—this study innovatively adopted an ion-doping strategy to successfully fabricate Co2+-doped ZIF-8 small nanocrystal carriers under mild room temperature conditions, avoiding harsh reaction environments that may impair material performance. Endowed with a unique porous structure and large specific surface area, the as-prepared carrier exhibited excellent drug-loading performance, achieving a maximum loading capacity of 84.4% for the widely used chemotherapeutic agent doxorubicin (DOX). Thus, a synergistic nanotherapeutic system (CFD) integrating chemodynamic therapy and chemotherapy was rationally constructed to leverage the complementary advantages of both modalities. In vitro cell experimental results demonstrated that after 24 hours of incubation, the chemo/chemodynamic synergistic nanosystem exerted a lethality rate of up to 87.1% against HeLa cervical cancer cells, which was significantly superior to that of either monotherapy (single chemotherapy or chemodynamic therapy alone). This finding fully confirms that the CFD nanotherapeutic system possesses potent in vitro anticancer activity, as it can synergistically leverage the merits of both treatment modalities to enhance therapeutic efficacy and effectively overcome the limitations of single-mode therapy. Collectively, this work provides a reliable experimental foundation and promising application prospects for subsequent in-depth in vivo tumor therapy research and potential clinical translation.

VL  - 13
IS  - 6
ER  -

Copy | Download

Author Information

Chen Yu-fei

Department of Chemical and Environmental Engineering，Hetao University, Bayannur, China

Biography: 陈宇菲，女，2002年出生，学士，研究方向为纳米材料的制备及应用研究。

Contact Email

http://orcid.org/0009-0004-3777-7021
Fan Bo-hua

Department of Chemical and Environmental Engineering，Hetao University, Bayannur, China

http://orcid.org/0009-0000-7784-5501
Chu Hui-yuan

Department of Chemical and Environmental Engineering，Hetao University, Bayannur, China

Biography: 楚惠元，女，1982年出生，博士，毕业于西北大学，河套学院讲师，研究方向为纳米材料的制备及应用研究。

Contact Email

http://orcid.org/0009-0006-3728-2381

Download PDF

Submit an Article

Figure 1

Figure 1. 图 1 流程图。
Figure 2

Figure 2. 图 2 合成的 Co/ZIF-8 材料的电镜图。
Figure 3

Figure 3. 图 3 合成的 Co/ZIF-8 材料与负载 DOX 前后的红外光谱。
Figure 图4 CFD在pH为5

图4 CFD在pH为5. .0、6.8或7.4（37°C）的条件下，DOX的释放曲线DOX负载量随DOX浓度变化。
Figure 5

Figure 5. 图 5 在25°C和1mM H₂O₂条件下不同浓度的CFD反应5min后的吸收光谱。
Figure 6

Figure 6. 图 6 癌细胞相对存活率。

Table 1

表1 Co/ZIF - 8细胞毒性检测数据。
Table 2

表2 Co/ZIF-8@DOX细胞毒性检测数据。

Plain Text BibTeX RIS

APA Style

Yu-fei, C., Bo-hua, F., Hui-yuan, C. (2025). Preparation of Novel Co/ZIF-8 Nanocomposites and Evaluation of Their Anticancer Cell Performance in Vitro. Science Discovery, 13(6), 125-130. https://doi.org/10.11648/j.sd.20251306.14

Copy | Download

ACS Style

Yu-fei, C.; Bo-hua, F.; Hui-yuan, C. Preparation of Novel Co/ZIF-8 Nanocomposites and Evaluation of Their Anticancer Cell Performance in Vitro. Sci. Discov. 2025, 13(6), 125-130. doi: 10.11648/j.sd.20251306.14

Copy | Download

AMA Style

Yu-fei C, Bo-hua F, Hui-yuan C. Preparation of Novel Co/ZIF-8 Nanocomposites and Evaluation of Their Anticancer Cell Performance in Vitro. Sci Discov. 2025;13(6):125-130. doi: 10.11648/j.sd.20251306.14

Copy | Download

@article{10.11648/j.sd.20251306.14,
  author = {Chen Yu-fei and Fan Bo-hua and Chu Hui-yuan},
  title = {Preparation of Novel Co/ZIF-8 Nanocomposites and Evaluation of Their Anticancer Cell Performance in Vitro
},
  journal = {Science Discovery},
  volume = {13},
  number = {6},
  pages = {125-130},
  doi = {10.11648/j.sd.20251306.14},
  url = {https://doi.org/10.11648/j.sd.20251306.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sd.20251306.14},
  abstract = {To address the inherent limitations of single-mode cancer therapy—such as low efficacy, high susceptibility to drug resistance, and the inability to completely eliminate residual tumor cells—this study innovatively adopted an ion-doping strategy to successfully fabricate Co2+-doped ZIF-8 small nanocrystal carriers under mild room temperature conditions, avoiding harsh reaction environments that may impair material performance. Endowed with a unique porous structure and large specific surface area, the as-prepared carrier exhibited excellent drug-loading performance, achieving a maximum loading capacity of 84.4% for the widely used chemotherapeutic agent doxorubicin (DOX). Thus, a synergistic nanotherapeutic system (CFD) integrating chemodynamic therapy and chemotherapy was rationally constructed to leverage the complementary advantages of both modalities. In vitro cell experimental results demonstrated that after 24 hours of incubation, the chemo/chemodynamic synergistic nanosystem exerted a lethality rate of up to 87.1% against HeLa cervical cancer cells, which was significantly superior to that of either monotherapy (single chemotherapy or chemodynamic therapy alone). This finding fully confirms that the CFD nanotherapeutic system possesses potent in vitro anticancer activity, as it can synergistically leverage the merits of both treatment modalities to enhance therapeutic efficacy and effectively overcome the limitations of single-mode therapy. Collectively, this work provides a reliable experimental foundation and promising application prospects for subsequent in-depth in vivo tumor therapy research and potential clinical translation.
},
 year = {2025}
}

Copy | Download

TY  - JOUR
T1  - Preparation of Novel Co/ZIF-8 Nanocomposites and Evaluation of Their Anticancer Cell Performance in Vitro

AU  - Chen Yu-fei
AU  - Fan Bo-hua
AU  - Chu Hui-yuan
Y1  - 2025/12/10
PY  - 2025
N1  - https://doi.org/10.11648/j.sd.20251306.14
DO  - 10.11648/j.sd.20251306.14
T2  - Science Discovery
JF  - Science Discovery
JO  - Science Discovery
SP  - 125
EP  - 130
PB  - Science Publishing Group
SN  - 2331-0650
UR  - https://doi.org/10.11648/j.sd.20251306.14
AB  - To address the inherent limitations of single-mode cancer therapy—such as low efficacy, high susceptibility to drug resistance, and the inability to completely eliminate residual tumor cells—this study innovatively adopted an ion-doping strategy to successfully fabricate Co2+-doped ZIF-8 small nanocrystal carriers under mild room temperature conditions, avoiding harsh reaction environments that may impair material performance. Endowed with a unique porous structure and large specific surface area, the as-prepared carrier exhibited excellent drug-loading performance, achieving a maximum loading capacity of 84.4% for the widely used chemotherapeutic agent doxorubicin (DOX). Thus, a synergistic nanotherapeutic system (CFD) integrating chemodynamic therapy and chemotherapy was rationally constructed to leverage the complementary advantages of both modalities. In vitro cell experimental results demonstrated that after 24 hours of incubation, the chemo/chemodynamic synergistic nanosystem exerted a lethality rate of up to 87.1% against HeLa cervical cancer cells, which was significantly superior to that of either monotherapy (single chemotherapy or chemodynamic therapy alone). This finding fully confirms that the CFD nanotherapeutic system possesses potent in vitro anticancer activity, as it can synergistically leverage the merits of both treatment modalities to enhance therapeutic efficacy and effectively overcome the limitations of single-mode therapy. Collectively, this work provides a reliable experimental foundation and promising application prospects for subsequent in-depth in vivo tumor therapy research and potential clinical translation.

VL  - 13
IS  - 6
ER  -

Copy | Download